Sun Pharma's ILUMYA approved by U.S. FDA for adults with active psoriatic arthritis
Sun Pharma announced on 30 October 2026 that the U.S. FDA approved its supplemental BLA for ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis.
By ScoutQuest · · 1 min read
- FDA approval
- supplemental BLA for ILUMYA (tildrakizumab-asmn) for treating adults with active psoriatic arthritis
- Approval date
- 30 October 2026
- Indication extension
- extends ILUMYA beyond plaque psoriasis
- Release
- Press release
📌 The U.S. Food and Drug Administration approved the supplemental Biologics License Application for ILUMYA (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis, Sun Pharmaceutical Industries announced on 30 October 2026.
📌 Rick Ascroft, North America CEO, Sun Pharma, said the approval builds on ILUMYA's clinical experience in plaque psoriasis and that ILUMYA is now an option for adults with active psoriatic arthritis unable to self-administer treatment or who may benefit from regular in-office care.
🌍 The company says ILUMYA is an IL-23 inhibitor administered exclusively by a healthcare provider; ILUMYA is also approved for moderate-to-severe plaque psoriasis in India, Australia, Canada, China and Japan, and is sold as ILUMETRI in Europe by Almirall.
📌 ILUMYA was approved by the FDA in 2018 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, the release says.
Also from Sun Pharmaceutical Industries
Board approves Deloitte as statutory auditor for five years after existing auditor's term ends
30 Oct 2026
Consolidated results for the quarter ended 30.09.2026
30 Oct 2026
Allotment of rated, listed, unsecured NCDs of INR 7,816 crore on private placement basis
26 Oct 2026
More numbers
- Americans living with psoriatic arthritis2.4 million
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.